“生物药”--Wharton’s jelly源间充质干细胞

“生物药”--Wharton’s jelly源间充质干细胞
高连如
【期刊名称】《转化医学杂志》
【年(卷),期】2016(5)4
【摘要】干细胞治疗代表生物冶疗进入到了一个崭新的时代。

间充质干细胞是存在于胚胎或成体组织中来源于中胚层具有多向分化潜能的干细胞。

由于成体间充质干细胞的质量与数量自身缺陷,使之应用受到了很大限制。

Wharton’s jelly组织,是起始于胚胎发育第13天的胚外中胚层组织。

使用基因微阵列分析及功能分析,首次发现Wharton’s jelly源间充质干细胞( Wharton’s jelly derived mesenchymal stem cells,WJMSCs)高表达胚胎早期干性基因及心肌细胞分化早期特异转录因子,可分化心肌细胞等多种细胞。

进而,应用临床级WJMSCs经冠状动脉移植治疗ST抬高型急性心肌梗死患者的随机双盲临床试验,首次证明WJMSCs可明显改善心肌活力及心脏功能。

因此,WJMSCs具有极其重要益处；无伦理涉及,有强的分化潜能,无致瘤性；加之,WJMSCs可作为产品,在任何时候病情需要时立即应用。

为此,WJMSCs作为真正意义上的干细胞族,将最有希望成为具有应用前景的干细胞生物药。

%Cell-based treatment represents a new generation in the evolution of biological therapeutics. Mesenchymal stem cells ( MSCs) are mesoderm-derived multipotent stromal cells that reside in embryonic and adult tissues. The use of adult MSCs is limited by the quality and quantity of host stem cells. Wharton’s jelly of the umbilical cord originates from the extraembryonic and/or the embryonic mesoderm at day 13 of embryonic development. Using Affymetrix GeneChip
microarray and functional network analyses, we found for the first time that Wharton’s jelly-derived MSCs ( WJMSCs) , except for their expression of stemness molecular markers in common with human ESCs ( hESCs) , exhibited a high expression of early cardiac transcription factor genes and could be in-duced to differentiate into cardiomyocyte-like cells. Further, we demonstrated for the first time that intracoronary delivery of prepared clinical-grade WJMSCs was safe in treating patients with an ST-AMI attack by double-blind, randomized controlled trial and could significantly improve myocardial viability and heart function. It is therefore important to consider the benefits of WJMSCs, which are not ethically sensitive, have differentiation potential, and do not have the worrying issue of teratoma formation. Moreover, as the off the shelf product, WJMSCs can be applied immediately, and on de-mand. Thus, WJMSCs constitute a true stem cell population and are promising cells as a biological drug for stem cell-based therapies.
【总页数】5页(P193-197)
【作者】高连如
【作者单位】100048 北京，海军总医院心脏中心
【正文语种】中文
【中图分类】R329.2+4
【相关文献】
1.人脐带Wharton's Jelly来源间充质干细胞与人牙周膜干细胞成骨分化能力的对比研究 [J], 黄银莉;周洪;苏晓霞;钟天宇
2.脐带Wharton's Jelly中间充质干细胞的生物学特性 [J], 李晓玲;朱旅云;赵芳
3.人脐带Wharton's jelly源间充质干细胞培养中碱性成纤维细胞生长因子的作用[J], 巴云涛;谷晨熙;雷宁静;王晓薇;关方霞;胡祥;杨波;杜英;张天祥;田毅;乔晓俊;王成春
4.人脐带Wharton's Jelly来源间充质干细胞和人牙周膜干细胞复合PHBHHx、PHBV支架成骨分化能力的体外研究 [J], 黄银莉;周洪;卢晓云;苏晓霞;钟天宇
parison between the therapeutic effects of differentiated and undifferentiated Wharton’s jelly mesenchymal stem cells in rats with streptozotocin-induced diabetes [J], Chen-Yuan Hsiao;Tien-Hua Chen;Ben-Shian Huang;Po-Han Chen;Cheng-Hsi Su;Jia-Fwu Shyu;Pei-Jiun Tsai
因版权原因，仅展示原文概要，查看原文内容请购买。